93 research outputs found
HIGH DOSE OF IDARUBICIN-BASED REGIMEN FOR DIFFUSE LARGE CELL AIDS-RELATED NON-HODGKIN'S LYMPHOMA WITH OR WITHOUT ANTIRETROVIRAL THERAPY DURING ANTINEOPLASTIC AGENTS
No full textSUDDEN BLASTIC CRISIS (BC) IN CML PH+ PATIENTS IN COMPLETE CYTOGENETIC REMISSION (CCR) INDUCED BY IMATINIB
No full textSUDDEN BLASTIC CRISIS IN CML PH+ PATIENTS IN COMPLETE CYTOGENETIC REMISSION INDUCED BY IMATINIB
No full textGamma-delta hepatosplenic T-cell lymphoma. Description of a case with immunophenotypic and molecular follow-up succesfully treated with chemotherapy alone
No full textThis study hereby reports the case of a 19-year old boy with a gamma-delta hepatosplenic T-cell lymphoma (HSTCL). Initial therapy consisted of four cycles of the IEV (Ifosphamide, Epirubicin and Etoposide) scheme. Further treatment strategy was then adapted according to minimal residual disease monitoring by immunophenotypic and T-cell receptor gamma chain gene evaluation. The patient remains in complete clinical, immunological and molecular remission and in good clinical conditions 48 months after diagnosis and 40 months after stopping therapy
Distribution of genetic and molecular prognostic markers in young patients with Chronic Lymphocytic Leukemia (CLL) in different phases of the disease.
No full text
Possibility of progenitor cell mobilization during the hematological recovery following peripheral blood stem cell autograft.
No full textTwenty-four patients with hematological malignancies were studied during recovery following autografting in order to establish the proportion of patients that show CD34+ cell mobilization and the kinetics of mobilized CD34-positive cells. The patients showed a peak in peripheral blood (PB) CD34+ cells after a median of 14 days (range 12-20) following reinfusion. According to the number of circulating CD34+ cells, two groups could be clearly distinguished: 17 patients (group A) with 10 CD34+ cells/microl (median 51, range 13-123). Compared to group A, patients of group B showed a faster hematological reconstitution of both polymorphonuclear leukocytes >500/microl (12 vs. 15 days) and platelets >50,000/microl (12 vs. 17 days). The expression of the beta1 integrin CD49d was similar in the two groups of patients, while a lower expression of the beta2 integrin CD11a and a greater expression of the L-selectin CD62L were observed in the PB CD34+ cells of group B patients. Both in the PB and in the BM, the number of CFU-GEMM, CFU- GM, CFU-E and BFU-E of group B was significantly greater than that of group A. However, when the clonogenic potential of a single CD34+ cell was evaluated, no major differences in the number of colonies produced per CD34+ cell were found between the two groups
Monitoring of CD34+ cells during leukapheresis allows a single, successful collection of hemopoietic progenitors in patients with low numbers of circulating stem cells.
No full textWe have studied a total of 188 patients with hematological malignancies, submitted to mobilization therapy with G-CSF associated or not with chemotherapy in order to: (1) establish the lower limit of circulating progenitor cells that allows the collection of 2 x 10(6) CD34+ cells/kg by a single leukapheresis, utilizing the instrument set on standard parameters; (2) evaluate whether the number and quality of CD34+ cells collected remain stable during leukapheresis; and (3) collect a sufficient number of circulating CD34+ cells by a single procedure in patients in whom such an approach would have been insufficient to reach the target with the instrument set on standard parameters. The retrospective analysis conducted in 85 patients showed that 19 circulating CD34+ cells/microl represented the cut-off number capable of discriminating between patients who will require one or more apheresis to collect 2 x 10(6) CD34+ cells/kg. The validity of this value was prospectively confirmed in 70 subsequent patients. Based on in vitro results that showed the stability in the number of CD34+ cells, the proportion of different CD34+ cell subpopulations and the clonogenic capacity of the stem cell compartment during leukapheresis both in the blood of the patients and in samples taken directly from the instrument, we have adapted the blood volume to be processed in 33 patients with <19 PB CD34+ cells/microl. Stem cell collection was monitored during the leukapheresis and the procedure was prolonged for a time period estimated to be sufficient to reach the target number of CD34+ cells with a single procedure. The median increment of the total blood volume processed, calculated from the volume set automatically by the instrument was 25.2%, with a median of 3.3-fold total blood volume processed. In all cases, a sufficient CD34+ cell collection was completed in a single procedure. After autograft, the pattern of blood reconstitution was similar to that of all the other patients
HODGKIN'S DISEASE IN HIV-INFECTED PATIENTS:REPORT OF CASES USEFULLY TREATED WITH DOXORUBICIN,BLEOMYCIN, VINBLASTINE, AND DACARBAZINE (abvd) PLUS GRANULOCYTE COLONY-STIMULATING FACTOR
No full textNeoplastic bone marrow invasion:rapid exclusion of hematological disease by flow cytometric routine panels
No full textMultiparametric flow cytometry is an extensively used technique to assess the presence of different cellular populations in immunology and hematology. During routine immunophenotyping analysis, it is not uncommon to face cells of non-hemopoietic origin, negative for CD45 and other myeloid, megakaryocytic, B and T lineage antigens and positive for at least one antibody among CD56, CD117 and CD138. If cytology cannot identify cell origin, especially in cases of unclear interpretation, the contribution of multiparametric flow cytometry analysis can be crucial. We report 6 patients with a clinical suspicion of hematological disease in which multiparametric flow cytometry was extremely useful to quickly exclude blood disorders in order to initiate patients to the most appropriate diagnostic process
- …
